0001829126-26-004495
SEC filingThis amended annual report details a critical CEO transition and governance restructuring following the company's March 2025 Nasdaq direct listing, marking a strategic pivot from a founder-led scientific venture toward a commercially focused public entity.
The most significant development disclosed in this amendment is the October 2025 chief executive officer transition. Dr. Thomas Chen, a neurosurgeon and the company's founder, stepped down as CEO to assume the roles of Chief Medical Officer and Chief Scientific Officer. Amir Heshmatpour, who had served as Executive Chairman, assumed the CEO role. This transition suggests a pivot from the scientific and clinical development phase toward a more commercially focused strategy. Heshmatpour's background in restructuring and taking biotech companies public, including his role in the Shuttle Pharmaceuticals IPO, positions him to lead NeOnc through its next phase as a Nasdaq-listed entity. The timing, occurring just seven months after the March 2025 direct listing, indicates an acceleration of this strategic shift.
The filing addresses several governance matters required for Nasdaq compliance. The board composition now includes a majority of independent directors, with Bader Almonawer, Dr. Victoria Medvec, Dr. Steven Giannotta, and Jim Delshad qualifying as independent. The audit committee is chaired by Almonawer, designated as an audit committee financial expert. The company adopted a clawback policy compliant with Nasdaq standards, covering incentive-based compensation for executive officers. Late Section 16 filings by several officers and directors were disclosed, though the company stated its belief that all filing requirements were otherwise met. These governance enhancements position the company to meet the heightened scrutiny expected of a public entity.